Swiss drug maker Novartis announced over the weeknd that the company’s investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist had failed in a late-stage trial for a type of advanced skin cancer. The company said the drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous … Continue reading “Novartis Investigational Immuno-oncology Drug Fails Skin Cancer Trial”
